Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by pelabooston Jun 02, 2024 1:25pm
204 Views
Post# 36068359

Mouse Models

Mouse Models
I am responding with a new post as I have no idea how this new system at SH works. Nor do I care.

James Allison, Nobel Prize winner 2018, and his spouse, Scientific Advisor to ONC, Padmanee Sharma come to mind. I trust they are still together, and she is still with ONC. One never knows these days as there seems to be a dearth of updates on personnel. Jim believed in mouse models and as a layperson that is good enough for me. For those interested in Jim Allison and what we are talking about here for the most part. Read - Jim Allison believed in the power of T-Cells - when hardly anyone else did.

My concern with ONC and mouse models lies with the heavy touting of CAR T and the not yet famous Pela Boost. One can only hope that any pharma looking at ONC are also interested in the CAR T data. I cannot remember the last time the very promising CAR T data was mentioned.

We wait patiently.
<< Previous
Bullboard Posts
Next >>